What is the pharmacokinetic profile of PT-141 following subcutaneous injection, including half-life, peak concentration, and clearance?

What Is the Pharmacokinetic Profile of PT-141 Following Subcutaneous Injection?

PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide that acts as a melanocortin receptor agonist, primarily targeting MC3 and MC4 receptors in the central nervous system. Following subcutaneous injection, it is FDA-approved under the brand name Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Its pharmacokinetic profile—including half-life, peak concentration (C_max), and total body clearance (CL)—is characterized by rapid absorption, a short terminal half-life, and dose-proportional exposure, though detailed data on these parameters are not available in the provided research corpus.

What the AI assistants say

AI assistants collectively describe a detailed pharmacokinetic profile for bremelanotide (PT-141) following subcutaneous injection, citing specific values and mechanisms. They assert that the median time to peak concentration ($T_{text{max}}$) is approximately 1.03 hours after a 1.75 mg dose, indicating rapid absorption. They report that bremelanotide exhibits dose-proportional pharmacokinetics across therapeutic doses (0.75–1.75 mg), meaning systemic exposure (as measured by C_max and AUC) increases linearly with dose. The volume of distribution ($V_d$) is stated to be around 25.2 L in a 70 kg individual, suggesting distribution primarily within plasma and extracellular fluid. Plasma protein binding is reported as low (~21%), and metabolism is attributed to enzymatic hydrolysis by peptidases, with no significant involvement of cytochrome P450 enzymes. While the AI assistants do not explicitly state the terminal half-life or total body clearance, they imply a short half-life due to rapid clearance typical of small peptides.

What the research actually shows

The provided research corpus, which includes over 4,000 sources on peptide pharmacokinetics, controlled-release systems, monoclonal antibodies, oligonucleotides, and other therapeutic peptides such as insulin, leptin, growth hormone, and T-20, does not contain any information about PT-141 (bremelanotide) [1–15]. Despite comprehensive discussions on subcutaneous (SC) drug absorption, half-life calculations, clearance mechanisms, and the influence of molecular size and formulation on pharmacokinetics, PT-141 is not referenced in any of the cited studies or reviews.

For example, Source [1] discusses the lymphatic absorption of recombinant methionyl human leptin (r-metHu-leptin) in sheep, but this is unrelated to PT-141 [1]. Source [3] and [4] describe the pharmacokinetic behavior of proteins such as insulin, growth hormone, and monoclonal antibodies, noting that smaller peptides typically have shorter half-lives (e.g., minutes to hours), while larger molecules like antibodies can have half-lives of days [3, 4]. However, these generalizations do not apply specifically to PT-141. Source [15] provides a useful comparison of SC absorption kinetics based on molecular weight, noting that smaller peptides like anakinra (17.3 kDa) reach peak plasma concentrations (T_max) within 3–7 hours, whereas larger monoclonal antibodies like adalimumab (148 kDa) may take up to 5 days to reach T_max [15]. PT-141 is a synthetic 14-amino acid peptide with a molecular weight of approximately 1.7 kDa, placing it in the category of small peptides with potentially rapid absorption and short half-life. However, the exact pharmacokinetic parameters for PT-141 are not reported in the provided sources.

Similarly, while Source [5] details the pharmacokinetics of T-20 (enfuvirtide), a peptide used in HIV treatment, including a half-life of 1.8 hours and a steady-state concentration model based on a one-compartment system, this information is not transferable to PT-141 [5]. The same applies to the discussion of phosphorothioate oligonucleotides in Sources [11]–[13], which report terminal elimination half-lives of 40–60 hours in animals and longer in humans, but these are nucleic acid therapeutics, not peptides [11].

In summary, despite the comprehensive coverage of peptide and protein pharmacokinetics across the provided sources—including absorption, distribution, metabolism, excretion (ADME), half-life calculations (t_1/2 ≈ 0.693 V/CL), clearance, and the impact of formulation and route of administration—there is no data on PT-141. Therefore, it is not possible to determine its half-life, peak concentration, or clearance from the given references.

Where the AI consensus and the research diverge

The AI assistants provide a detailed, specific pharmacokinetic profile for bremelanotide, including values for $T_{text{max}}$, $V_d$, and implied half-life. However, these claims are not supported by the research corpus, which explicitly states that PT-141 is not mentioned in any of the referenced studies or reviews. The absence of any mention of PT-141 in a corpus of over 4,000 sources on peptide pharmacokinetics underscores a critical gap: the AI-generated information, while plausible and consistent with general principles of small peptide behavior, is not grounded in the evidence base provided. This divergence highlights a key risk in AI-generated medical content—plausibility does not equate to accuracy, especially when specific data are unavailable.

Bottom line: The pharmacokinetic profile of PT-141 following subcutaneous injection—including half-life, peak concentration, and clearance—cannot be determined from the provided sources, as PT-141 is not mentioned in any of the referenced studies or reviews [1–15].

References

1. Antisense Research and Application
2. Drug Delivery_ Engineering Principles for Drug Therapy
3. Gene Therapy_ Therapeutic Mechanisms and Strategies
4. Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic
5. Principles and Practice of the Biologic Therapy of Cancer
6. Rook's Textbook of Dermatology
7. Therapeutic Applications of Oligonucleotides
8. Therapeutic Peptides and Proteins Formulation, Processing — Ajay K Banga

Continue your research

Part of our PT-141: Dosing, Forms & Administration guide.

• What is the optimal dosing regimen for PT-141 in treating sexual dysfunction, including frequency, route (subcutaneous vs. intranasal), and titration protocols?
• How do dose-response relationships vary between individuals, and what factors (age, sex, weight, comorbidities) influence effective dosing?
• What is the recommended starting dose for PT-141 in clinical settings, and how is it adjusted based on response and side effects?

Related topics:

• Does PT-141 cross the blood-brain barrier effectively, and how does its pharmacokinetic profile support central nervous system activity?
• What are the implications of PT-141’s short half-life for dosing frequency and patient convenience?
• How does PT-141 influence body composition, including fat mass and lean mass, in human or animal studies, and what mechanisms are proposed?

📚 The 4,000+ sources behind PeptideXR →